<DOC>
	<DOCNO>NCT00495625</DOCNO>
	<brief_summary>An open label multi-site phase II clinical trial dose escalate sunitinib malate give orally daily day 1-28 42-day cycle . Treatment continue either disease progression cumulative acute toxicity opinion treat physician compromise ability patient receive treatment patient desire stop treatment .</brief_summary>
	<brief_title>Sunitinib Malate ( SUO11248 ) In Subjects W/ Metastatic And/Or Surgically Unresectable Hepatocellular Cancers ( HCC )</brief_title>
	<detailed_description>An open label multi-site phase II clinical trial sunitinib malate give orally daily day 1-28 42-day cycle . Sunitinib malate dispense capsule begin treatment cycle . The dose may escalate investigator 's discretion . Treatment continue either disease progression cumulative acute toxicity opinion treat physician compromise ability patient receive treatment patient desire stop treatment . A follow visit require begin every cycle every 6 week assess toxicity physical examination . Complete blood count ( CBC ) differential , comprehensive metabolic panel ( include liver function test ) alpha-feto protein ( indicate ) obtain every schedule follow visit .</detailed_description>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<criteria>Resolution acute toxic effect prior chemotherapy radiotherapy surgical procedure National Cancer Institute ( NCI ) Common Terminology Criteria Adverse Events ( CTCAE ) Version 3.0 grade less equal 1 . Adequate organ function define follow criterion : Serum aspartate transaminase ( AST ) ; serum glutamic oxaloacetic transaminase ( SGOT ) serum alanine transaminase ( ALT ) ; serum glutamic pyruvic transaminase ( SGPT ) less equal 2.5 x local laboratory upper limit normal ( ULN ) , AST ALT less equal 5 x ULN liver function abnormality due underlie malignancy Total serum bilirubin less equal 1.5 x ULN Absolute neutrophil count ( ANC ) equal 1500/mcL Platelets equal 100,000/mcL Hemoglobin equal 9.0 g/dL Serum calcium less equal 12.0 mg/dL Serum creatinine less equal 1.5 x ULN Biopsyproven disease Measurable disease radiographically Disease deem surgically unresectable ( await orthotopic hepatic transplantation allowable ) and/or metastatic Age great equal 18 year Life expectancy great 16 week Eastern Cooperative Oncology Group ( ECOG ) performance status 0 , 1 2 ( Karnofsky score &gt; 60 % ) Major surgery radiation therapy chemotherapy within 4 week start study treatment NCI CTCAE version 3 grade 3 hemorrhage within 4 week start study treatment History know brain metastasis , spinal cord compression , carcinomatous meningitis , evidence symptomatic brain leptomeningeal disease screen compute tomography ( CT ) magnetic resonance imaging ( MRI ) scan Any follow within 6 month prior study drug administration : myocardial infarction , severe/unstable angina , coronary/peripheral artery bypass graft , symptomatic congestive heart failure , cerebrovascular accident transient ischemic attack , pulmonary embolism . Known brain metastasis Ongoing cardiac dysrhythmias NCI CTCAE grade great equal 2 Ongoing cardiac dysrhythmias NCI CTCAE grade great equal 2 , atrial fibrillation grade , prolongation QTc interval &gt; 450msec male &gt; 470 msec female Hypertension control medication ( &gt; 150/100 mm Hg despite optimal medical therapy ) Preexisting thyroid abnormality thyroid function maintain normal range medication Known human immunodeficiency virus ( HIV ) acquire immunodeficiency syndrome ( AIDS ) relate illness active infection Concurrent treatment another clinical trial ; supportive care trial nontreatment trial , e.g . Quality Life ( QOL ) , allow Concomitant use ketoconazole agent know induce CYP3A4 Concomitant use theophylline phenobarbital and/or agent metabolize cytochrome P450 system Ongoing treatment therapeutic dos Coumadin ( low dose Coumadin 2 mg po daily thrombo prophylaxis allow ) Pregnancy breastfeed . Female subject must surgically sterile postmenopausal , must agree use effective contraception period therapy . All female subject reproductive potential must negative pregnancy test ( serum urine ) prior enrollment . Male subject must surgically sterile must agree use effective contraception period therapy . The definition effective contraception base judgment principal investigator designate associate . Other severe acute chronic medical psychiatric condition laboratory abnormality may increase risk associate study participation study drug administration , may interfere interpretation study result , judgment investigator would make subject inappropriate entry study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>Hepatocellular cancer ( HCC )</keyword>
	<keyword>Sunitinib malate</keyword>
	<keyword>Vascular endothelial growth factor ( VEGF )</keyword>
	<keyword>Platelet-derived growth factor ( PDGF )</keyword>
	<keyword>Tyrosine kinase</keyword>
	<keyword>Liver</keyword>
</DOC>